Svoz Dosage/Direction for Use

Svoz: Recommended Dose: Take Moxifloxacin 400 mg once daily.
Mode of Administration: Moxifloxacin can be taken without regard to meals or may be taken independent of meals and should be taken with liberal amounts of fluids. The duration of treatment depends on the severity of the indication and result of microbial culture test of acute infection.
Acute sinusitis: Take 1 tablet once daily for 10 days or following doctor's instruction.
Acute exacerbations of chronic bronchitis: Take 1 tablet once daily for 5 days or following doctor's instruction.
Community-acquired pneumonia: Take 1 tablet once daily for 7-14 days.
Uncomplicated skin and skin structure infections: Take 1 tablet once daily for 7 days.
Complicated skin and skin structure infections: Take 1 tablet once daily for 7-21 days (since initiated with Moxifloxacin IV formulation).
Therapy with Moxifloxacin should be initiated IV formulation following by oral formulation.
Complicated intra-abdominal infections: Take 1 tablet once daily for 5-14 days (since initiated with Moxifloxacin IV formulation).
Therapy with Moxifloxacin should be initiated IV formulation following by oral formulation.
Uncomplicated pelvic inflammatory disease: Take 1 tablet once daily for 14 days.
Patients with hepatic and renal impairment: No dose adjustment is required.
Geriatric patients: No dose adjustment is required.
Children and adolescents: Moxifloxacin is contraindicated in children or adolescents younger than 18 years of age as safety and efficacy have not been established in children or adolescents.
Svoz Infusion: Moxifloxacin solution for infusion should only be administered by the intravenous infusion over 60 minutes. Do not infuse by rapid or bolus intravenous infusion.
Moxifloxacin solution for infusion should not be admixed with other drugs or infused simultaneously through the same tubing with other drugs. If the same IV line or a Y-type line is used for sequential infusion of other drugs or if the piggyback method of administration is used, the tubing should be flushed before and after infusion of Moxifloxacin using an IV solution compatible with both Moxifloxacin and the other drug(s). Moxifloxacin solution for infusion should be inspected visually for particulate matter prior to administration; the premixed solution should appear yellow. Any unused portion of the solution should be discarded.
When administering via IV infusion, do not exceed the recommended dose or infusion rate to avoid risk of QT interval prolongation. Patients receiving intravenous Moxifloxacin should be well hydrated and instructed to drink fluids liberally.
Use in adults (18 years and older): The recommended dose for Moxifloxacin is 400 mg once daily.
The duration of treatment should be determined by the severity of the indication or clinical response. Therapy may be initial intravenous administration, followed by oral administration when clinically indicated.
Community-acquired pneumonia: The total treatment duration for sequential administration (intravenous followed by oral therapy) is 7-14 days.
Complicated skin and skin structure infections: The total treatment duration for sequential administration (intravenous followed by oral therapy) is 7-21 days.
Complicated intra-abdominal infections: The total treatment duration for sequential administration (intravenous followed by oral therapy) is 5-14 days.
The recommended duration of treatment for the indication being treated should not be exceeded.
Moxifloxacin 400 mg solution for infusion has been studied in clinical trials for up to 21 days (in complicated skin and skin structure infections).
Use in children and adolescents: Safety and efficacy of Moxifloxacin have not been established for any indication in children or adolescents younger than 18 years of age.
Use in patients with renal impairment: No dose adjustment is necessary for patients with renal impairment (including creatinine clearance ≤30 mL/min/1.73 m²) and in patients on chronic dialysis e.g. hemodialysis and continuous ambulatory peritoneal dialysis.
Use in hepatic impairment: No dose adjustment is necessary for patients with mild, moderate or severe hepatic insufficiency (Child Pugh Class A, B or C). However, Moxifloxacin should be used with caution in patients with hepatic impairment because the metabolic disturbances associated with hepatic insufficiency may lead to QT prolongation. ECGs should be monitored in patients with liver cirrhosis.
Use in the elderly: No adjustment of dosage is required in elderly.